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IIntroduction
Opioid receptors are the members of G-protein coupled receptor 
superfamily. The binding of opioid agonists to the receptor triggers a chain 
of signaling events, which are involved in the cellular mechanisms of pain 
control and drug addiction. The existence of three major types of opioid 
receptors, designated as mu, delta and kappa, is generally accepted. The 
synthesis of new, selective ligands with high affinity for a specific type of 
receptors is one of the important directions in the field of opioid research. 
New compounds can be employed as both pharmacological tools and 
potential therapeutic agents.
This thesis describes the characterization of several newly developed 
ligands acting preferably on mu and delta opioid receptors based on 
biochemical (radioligand binding) and functional (guanosine-5’-[y-35Sj- 
triphosphate ((3iS]GTPyS) binding) assays. Rat brain membrane 
preparations were used in these in vitro studies.
Ligands acting through delta opioid receptors play an important role 
in antinociception, immunoregulation, and can be useful for treatment of 
alcohol and drug addicts. Non-peptide compounds are of a big importance 
because of their ability to penetrate blood brain barrier and relative stability 
against enzymatic degradation. There is a big emphasis on the development 
of new selective antagonists, which, except for medicinal purposes, are used 
to evaluate the selectivity of new compounds and to study the interaction of 
endogenous ligands with different opioid receptors. In this study new non- 
peptide compounds based on the structure of naltrindole and naltriben, well 
known delta opioid antagonists, were investigated. According to the
2structural modifications it was expected that new compounds would 
demonstrate improved selectivity and/or affinity towards delta opioid 
receptor.
Until present days the majority of drugs clinically used for the pain 
control are mu opioid receptor selective ligands. Etorphine is a highly potent 
synthetic narcotic compound, which exerts its action mainly through mu 
opioid receptors. It is known to cause strong analgesia, catatonia and 
blockade of conditioned reflexes in laboratory animals. Etorphine is widely 
used for the immobilization of different types of animals in veterinarian and 
nature preservation practice. Since C18 ^-substituted structural analogues of 
etorphine compounds have not been studied until now, it is of considerable 
interest to investigate their features. Therefore a number of new 0- 
substituted etorphine ligands were synthesized and their binding and 
functional characteristics were examined in this study.
Endomorphin 1 and 2 (Tyr-Pro-Trp-Phe-NH2 and Tyr-Pro-Phe-Phe- 
NH2, respectively), two peptides which demonstrated high affinity and 
selectivity for mu opioid receptor, were isolated from bovine brain in 1997. 
Later endomorphins were found in human brain and immune tissues. 
Endomorphins, like other mu opioid receptor agonists, produce strong 
analgesic effect and were shown to take part in regulation of cardiovascular 
activity. Endomorphins were shown to.act through classical mu-opioid 
receptor pathway and activate G-proteins and inhibit adenylyl cyclase 
activity. In the present study we investigated how the enzymatic degradation 
would affect the binding and functional properties of endomorphins and the 
role of C-terminal of these peptides for efficient binding to opioid receptors.
3Aim of the studies
To investigate structure-activity relationships of newly developed 
analogues of well known non-peptide delta selective antagonists naltrindole 
and naltriben; to improve the selectivity and/or affinity of the resulted 
indolo- and benzofuromorphinans with focus on the 5- and 14-positions.
To investigate how structural modifications introduced to highly 
potent synthetic opioid compound etorphine will affect biochemical and 
functional properties of the ligands. To examine the effects of C18 0- 
substitution.
To assess the effects of possible enzymatic degradation of 
endomorphin 1 and. the influence of C-terminal structural modifications of 
endomorphin 2 on receptor binding and the consequent activation of G 
proteins.
Methods
Competition binding experiments
Binding experiments were carried out in 50 mM TRIS-HC1 buffer (pH 
7.4) in a final volume of 1 ml containing 0.3-0.4 mg protein. In experiments 
with [3H]EKC 100 nM DAMGO and [D-Ala2,Leus]enkephalin were added 
to the reaction mixture to block mu and delta binding sites. Incubations were 
started by addition of membrane suspension and terminated by rapid 
filtration using Brandel Cell Harvester through Whatman GF/B or GF/C
glass fibre filters and washed three times with 5 ml of ice-cold TRIS-HC1 
(50 mM, pH 7.4) buffer. The filters were dried at 37°C and the bound 
radioactivity determined in a toluene based scintillation cocktail using 
Wallac 1409 scintillation counter. All experiments were carried out in 
duplicates and repeated at least three times.
[^SJGTPyS binding
Tubes containing 10 pg protein, 30 pM GDP, opioid ligand and 0.05 
nM [35S]GTPyS, all in 50 mM Tris-HCl buffer containing 1 mM EGTA, 100 
mM NaCl and 3 mM MgCl2 in a final volume of 1 ml were incubated for 1 
h, at 30°C. Nonstimulated activity was measured in the absence of the tested 
compound, nonspecific binding was measured in the presence of 100 pM 
unlabelled GTPyS. The reaction was started by addition of [33S]GTPyS, and 
terminated by filtrating the samples through Whatman GF/B glass fiber 
filters. Filters were washed three times with ice-cold 50 mM Tris-HCl buffer 
(pH 7.4) using Brandell Cell Harvester, then dried, and radioactivity was 
measured in a Wallac 1409 scintillation counter (Turku, Finland) using a 
toluene based scintillation cocktail. Stimulation is given as percent of the 
specific binding. Data were calculated from at least three independent 
experiments performed in triplicates.
Respits and conclusions
All new indolo- and benzofuromorphinan compounds displayed high 
affinity for delta opioid binding sites. The compound with a methyl group at 
the 17-N position was found to be an agonist, thus confirming the 
5importance of the substituent at the morphinan nitrogen for 
agonist/antagonist features. All other compounds were antagonists. The 
presence of a methyl group in position 5 induced no change in delta affinity, 
but decreased the mu and kappa affinities. An ethoxy group at position 14 
conferred a very high affinity and also high selectivity to delta opioid 
receptors. Chain prolongation of the 14-alkoxy group resulted in compounds 
with reduced delta affinity and selectivity. The results demonstrate that 5- 
and 14-positions of indolo- and benzofuromoiphinans represent critical sites 
that can be successfully used to develop new compounds with increased 
affinity and selectivity for delta binding sites.
All new etorphine derivatives showed high affinity for mu opioid 
receptors. ^-Substituted etorphines had slightly lower affinities compared to 
the parent a-etorphines. Methylether derivatives were consistently weaker 
than the corresponding phenolic compounds. Dihydroetorphine and P- 
dihydroetorphine having partially saturated ring structure showed as good 
potency in the binding assays as did etorphine and P-etorphine with C7-C8 
double bonds. It was also found that C3 phenolic group is far more favorable 
for G-proteins activation. The results suggest that neither the configuration 
of Cl 8 nor the saturation of the C7-C8 double bond play a critical role in the 
biological activity of etorphines.
Both N- and C-terminal truncated endomorphin 1 derived peptides 
demonstrated considerably lower opioid receptor binding potency compared 
to the parent endomorphin 1. None of the truncated peptides had an effect on
6GTP binding. Obtained results suggest that degradation destroys the 
biological activity of endomorphin 1.
Peptides obtained as a result of the alteration of the C-terminal 
carboxamide group of endomorphin 2 generally demonstrated decreased 
affinity towards mu opioid receptor. The exception was E2-ol, where the 
amide group was replaced with an alcohol that resulted in increased affinity 
for mu binding sites. All derivatives had lower functional activity than 
parent endomorphin 2. It has been shown that the distance between the C- 
terminal aromatic ring and the peptide backbone has strong effect on the 
receptor binding and the functional activity of the peptides. Although the C- 
terminal carboxamide group can be eliminated from the molecule without 
serious loss of binding activity, for efficient receptor stimulation and 
naloxone antagonism at least one polar group is necessazy at the C-terminus. 
The data presented demonstrate that the C-terminal amide group has an 
essential role in the regulation of the binding and the agonist/antagonist 
properties of E2.
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